AIM Vaccine (6660) Stock Overview
Engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
6660 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AIM Vaccine Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$5.08 |
| 52 Week High | HK$15.48 |
| 52 Week Low | HK$3.03 |
| Beta | 0.16 |
| 1 Month Change | 34.04% |
| 3 Month Change | 57.76% |
| 1 Year Change | -20.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.51% |
Recent News & Updates
Recent updates
AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too
Jul 24
Take Care Before Jumping Onto AIM Vaccine Co., Ltd. (HKG:6660) Even Though It's 25% Cheaper
Apr 04Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt
Nov 15Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge
Aug 24It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)
May 29Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking
Jun 09Shareholder Returns
| 6660 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 26.4% | -0.3% | 2.5% |
| 1Y | -20.7% | 166.8% | 43.1% |
Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned 166.8% over the past year.
Return vs Market: 6660 underperformed the Hong Kong Market which returned 43.1% over the past year.
Price Volatility
| 6660 volatility | |
|---|---|
| 6660 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in HK Market | 15.3% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 6660 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6660's weekly volatility has decreased from 17% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 1,535 | Yan Zhou | www.aimbio.com |
AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.
AIM Vaccine Co., Ltd. Fundamentals Summary
| 6660 fundamental statistics | |
|---|---|
| Market cap | HK$6.23b |
| Earnings (TTM) | -HK$303.59m |
| Revenue (TTM) | HK$1.41b |
Is 6660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6660 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.29b |
| Cost of Revenue | CN¥331.52m |
| Gross Profit | CN¥953.51m |
| Other Expenses | CN¥1.23b |
| Earnings | -CN¥277.23m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 74.20% |
| Net Profit Margin | -21.57% |
| Debt/Equity Ratio | 50.4% |
How did 6660 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/27 21:21 |
| End of Day Share Price | 2025/07/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AIM Vaccine Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Fosun International Securities Limited |
| Tony Ren | Macquarie Research |